Genmab A/S (NASDAQ:GMAB) Expected to Post Quarterly Sales of $266.84 Million

Wall Street brokerages expect that Genmab A/S (NASDAQ:GMAB) will report sales of $266.84 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Genmab A/S’s earnings, with the lowest sales estimate coming in at $247.87 million and the highest estimate coming in at $288.28 million. Genmab A/S posted sales of $804.62 million during the same quarter last year, which suggests a negative year-over-year growth rate of 66.8%. The company is expected to issue its next quarterly earnings report on Wednesday, August 11th.

On average, analysts expect that Genmab A/S will report full-year sales of $1.24 billion for the current fiscal year, with estimates ranging from $1.17 billion to $1.32 billion. For the next year, analysts forecast that the company will post sales of $1.58 billion, with estimates ranging from $1.49 billion to $1.75 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Genmab A/S.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.22. The firm had revenue of $256.24 million during the quarter, compared to analysts’ expectations of $214.90 million. Genmab A/S had a net margin of 51.35% and a return on equity of 29.11%.

Several research firms recently weighed in on GMAB. TheStreet raised shares of Genmab A/S from a “c” rating to a “b” rating in a research note on Monday, May 24th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Genmab A/S in a research note on Wednesday. Truist lifted their price objective on shares of Genmab A/S from $42.00 to $47.00 in a research note on Thursday, February 25th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Genmab A/S in a research note on Friday, May 28th. Finally, HC Wainwright reissued a “buy” rating on shares of Genmab A/S in a research note on Thursday, February 11th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. Genmab A/S presently has a consensus rating of “Hold” and an average target price of $42.13.

A number of institutional investors and hedge funds have recently made changes to their positions in GMAB. Janney Montgomery Scott LLC lifted its holdings in Genmab A/S by 8.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 8,034 shares of the company’s stock valued at $327,000 after buying an additional 604 shares in the last quarter. Comerica Bank raised its holdings in shares of Genmab A/S by 10.3% in the 4th quarter. Comerica Bank now owns 41,595 shares of the company’s stock valued at $1,791,000 after purchasing an additional 3,893 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Genmab A/S by 96.5% in the 4th quarter. First Trust Advisors LP now owns 719,688 shares of the company’s stock valued at $29,263,000 after purchasing an additional 353,483 shares in the last quarter. Altium Wealth Management LLC bought a new stake in shares of Genmab A/S in the 4th quarter valued at about $323,000. Finally, Vestmark Advisory Solutions Inc. raised its holdings in shares of Genmab A/S by 7.5% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 18,975 shares of the company’s stock valued at $772,000 after purchasing an additional 1,326 shares in the last quarter. Institutional investors own 6.42% of the company’s stock.

GMAB traded up $0.16 during trading on Tuesday, hitting $43.79. 18,852 shares of the company traded hands, compared to its average volume of 543,409. The company has a market cap of $28.74 billion, a P/E ratio of 33.56, a PEG ratio of 2.69 and a beta of 0.89. The stock has a 50-day moving average price of $37.45. Genmab A/S has a 1 year low of $29.06 and a 1 year high of $44.83.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL.

Featured Article: What is required to own or exchange cryptocurrency?

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.